TRUST
Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer
(ENGOT ov33 / AGO-OVAR OP.7)
Who does this research impact?
- People with suspected or diagnosed cancer of the ovary, the fallopian tube or the peritoneum.
How were the participants treated?
- This international study included 688 people with confirmed newly diagnosed cancer that spread to the abdomen and/or chest, FIGO stage IIIB, IIIC, IVA and IVB and who were not previously treated for this disease.
- Study participants were randomly assigned to receive either primary cytoreductive surgery followed by standard systemic therapy (345 participants) or three cycles of neoadjuvant chemotherapy, then interval cytoreductive surgery, followed by three additional cycles of chemotherapy (343 participants).
- All participants were treated with standard chemotherapy. This included carboplatin and paclitaxel. Bevacizumab and PARP-inhibitors were also given if indicated. The type of systemic therapy was selected by the doctor treating the patient.
- All participating study centers had to pass a rigorous qualification process, to allow for transparent and adequate surgical quality.
This was a central part of the TRUST study.
What did the study find? What does this mean for patients right now?
- The study found that the timing of surgery, either prior to systemic therapy or after three cycles of neoadjuvant chemotherapy, did not make a big difference in survival, but surgery prior to chemotherapy delayed tumor regrowth and prolonged remission as compared to neoadjuvant chemotherapy.
- Especially for participants with cancer confined to the abdomen (FIGO stage III), a long term benefit was seen for primary surgery over interval surgery. After 5 years, 23% of the participants in the primary surgery group were still in remission, as compared to 11% in the interval surgery group.
- A benefit of surgery was mainly seen for participants where all visible tumor could be removed during the surgery. Primary surgery prolonged remission 6 months more than interval surgery, and participants lived an average of 1 year longer after primary surgery as compared to interval surgery. The result of surgery is however only known after it was performed, so this information is not known in each individual when making the decision to start primary surgery or neoadjuvant chemotherapy.
- Serious complications after surgery were generally low. Primary surgery took the surgeons about 1 hour longer than interval surgery (5 ½ hours compared to 4 ½ hours) and had slightly more complications.
- Quality of life of the participants did not differ between the two groups.
- The high rate of successful surgery, together with low complication rates and subsequent long survival in both treatment groups demonstrates also, that centralized patient care and surgery in centers with surgical quality assurance programs play an important role to survive cancer of the ovary, fallopian tube or peritoneum.
Bei diesem Medudy-Kurs handelt es sich um ein Video-Tutorial für Ärztinnen und Ärzte zum Thema „TRUST-Studie beim Ovarialkarzinom”.
Diese Studie wird vom KI-Avatar von Prof. Mahner, dem Studienleiter der TRUST-Studie, vorgestellt. Die Studie untersucht den optimalen Zeitpunkt der zytoreduktiven Operation beim fortgeschrittenen Ovarialkarzinom. Die Ergebnisse dieser Studie wurden erstmals auf der ASCO-Jahrestagung 2025 präsentiert.
Anmerkung: Alle in den Medudy-Videos erscheinenden „Rednerinnen und Redner” sind KIbasierte Avatare, die zur besseren Didaktik der Videos eingesetzt werden. Die Personen, auf denen die Avatare basieren, haben der Verwendung explizit zugestimmt.
Alle Inhalte basieren auf hochwertigen wissenschaftlichen Quellen und werden vom Medudy-Ärzt:innenteam erstellt sowie überprüft.
Am Ende dieser Fortbildung kennen Sie:
- die klinischen Hintergründe und Relevanz der untersuchten Forschungsfrage
- Studiendesign und Methodik der Publikation zur Beantwortung der Forschungsfrage
- die Ergebnisse und wichtigsten Takeaways der Publikation
- das Fazit der Publikation sowie mögliche Limitationen
This Medudy course is a video tutorial for physicians on the topic of “TRUST Trial in Ovarian Cancer”.
This study is presented by the AI avatar of Professor Mahner, the Principal Investigator of the TRUST trial. The study explores the optimal timing of cytoreductive surgery in advanced ovarian cancer. The results of this study were first presented at the 2025 ASCO Annual Meeting.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used for better didactics. The people on which the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by Medudy’s medical team.
At the end of this tutorial, you will know:
- the publication’s background on why this research question is relevant
- the publication’s study design and methods to answer this research question
- the publication’s results and main takeaways
- the publication’s conclusion as well as potential limitations
Questo corso Medudy è un video tutorial pensato per i medici e dedicato allo studio TRUST sul tumore ovarico.
La presentazione è affidata all’avatar AI del Professor Mahner, ricercatore principale dello studio TRUST. L’indagine si concentra sul momento più appropriato per eseguire la chirurgia citoriduttiva nei casi di tumore ovarico avanzato. I risultati sono stati presentati per la prima volta al Congresso Annuale ASCO del 2025.
Nota: Tutti i "relatori" presenti nei video Medudy sono avatar generati dall’intelligenza artificiale, utilizzati per rendere la didattica più efficace. Le persone a cui gli avatar si ispirano hanno dato il loro esplicito consenso. I contenuti sono basati su fonti scientifiche di alta qualità e vengono elaborati e verificati dal team medico di Medudy.
Al termine del tutorial avrai acquisito:
- una comprensione del contesto scientifico che ha motivato questa ricerca
- una panoramica del disegno dello studio e dei metodi utilizzati
- un’analisi dei risultati principali e dei punti chiave
- le conclusioni dello studio, insieme a un’eventuale discussione sui suoi limiti
Este curso de Medudy es un videotutorial dirigido a médicos sobre el ensayo TRUST en cáncer de ovario.
La presentación está a cargo del avatar de inteligencia artificial del Profesor Mahner, investigador principal del ensayo TRUST. El estudio analiza cuál es el mejor momento para realizar la cirugía citorreductora en el cáncer de ovario avanzado. Los resultados se presentaron por primera vez en el Congreso Anual de ASCO 2025.
Nota: Todos los "presentadores" que aparecen en los videos de Medudy son avatares generados por inteligencia artificial con fines didácticos. Las personas en quienes se basan han dado su consentimiento explícito para su uso. Todo el contenido está basado en fuentes científicas de alta calidad y ha sido desarrollado y revisado por el equipo médico de Medudy.
Al finalizar este tutorial, sabrás:
- el contexto y la relevancia de la pregunta de investigación
- el diseño del estudio y la metodología utilizada
- los hallazgos principales del estudio y sus aspectos más destacados
- la interpretación final del estudio, así como sus posibles limitaciones
Ce cours Medudy est un tutoriel vidéo destiné aux médecins sur le thème « L'essai TRUST dans le cancer de l'ovaire.
Cette étude est présentée par l'avatar IA du professeur Mahner, chercheur principal de l'essai TRUST. L'étude explore le moment optimal pour la chirurgie cytoréductive dans le cancer de l'ovaire avancé. Les résultats de cette étude ont été présentés pour la première fois lors de la réunion annuelle 2025 de l'ASCO.
Remarque : tous les « intervenants » apparaissant dans les vidéos Medudy sont des avatars basés sur l'IA utilisés à des fins didactiques. Les personnes sur lesquelles ces avatars sont basés ont donné leur consentement explicite à leur utilisation. Tout le contenu est basé sur des sources scientifiques de haute qualité et est créé et révisé par l'équipe médicale de Medudy.
À la fin de ce tutoriel, vous aurez acquis les connaissances suivantes :
- le contexte de la publication expliquant pourquoi cette question de recherche est pertinente
- la conception de l'étude et les méthodes utilisées dans la publication pour répondre à cette question de recherche
- les résultats de la publication et les principaux enseignements à en tirer
- la conclusion de la publication ainsi que ses limites potentielles
